代谢组学分析预测IgA血管炎肾炎的生物标志物
该研究对45例活动性IgA血管炎(IgAV)患者和6例健康对照的血浆进行非靶向代谢组学分析,随访中6例发生肾炎(IgAVN),中位时间23天。发现DHAP(18:0)、前列腺素D2/I2、卟胆原、5-甲基四氢叶酸和N-乙酰-4-O-乙酰神经氨酸/N-乙酰-7-O-乙酰神经氨酸可能作为预测肾脏疾病的生物标志物。
要点
- 45例IgAV患者中6例随访发生IgAVN,中位时间23天。
- 代谢组学发现39个共同差异峰,15个推定代谢物匹配11个峰作为候选标志物。
- 候选标志物包括DHAP(18:0)、前列腺素D2/I2、卟胆原等,需更大样本验证。
核心结论
- DHAP(18:0)、前列腺素D2/I2、卟胆原、5-甲基四氢叶酸和N-乙酰-4-O-乙酰神经氨酸/N-乙酰-7-O-乙酰神经氨酸可能作为预测IgAV肾脏疾病的生物标志物。
研究设计与样本
- 纳入45例活动性IgAV患者和6例健康对照,诊断时采集血浆,采用四极杆飞行时间质谱(Q-TOF LC/MS)进行非靶向代谢组学分析。
主要发现
- 随访中6/45例IgAV患者发生IgAVN,中位时间23天(范围5-45天)。
- 发生与未发生肾脏受累的患者在性别、年龄、临床表现和实验室检查上无显著差异。
- 多变量分析显示男性、胃肠道受累、关节受累、CRP、WBC、PLT与肾脏受累发生无显著关联。
- 共检测2618个峰,355个峰有统计学意义(p<0.05),其中155个峰在C组与H组间变化倍数>1.5,66个峰在H组与N组间变化倍数>1.5,39个峰为两组比较的交集。
- 基于推定鉴定结果,15个推定代谢物匹配11个峰,经临床评估后作为候选生物标志物。
关键数值与推荐
- 差异峰筛选标准:p<0.05且变化倍数>1.5。
- IgAVN诊断依据:随访中出现肾病性蛋白尿、肾病综合征性蛋白尿或镜下血尿。
临床怎么用
- 诊断IgAV时无肾脏受累的患者,可考虑检测候选代谢标志物以预测IgAVN风险。
- 候选标志物需在更大样本IgAV患者中验证后才能用于临床决策。
局限性
- 样本量小(45例IgAV患者,6例健康对照),IgAVN事件仅6例。
- 代谢物鉴定为推定鉴定,未进行绝对定量验证。
- 需要更大规模研究验证代谢谱。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: IgA vasculitis (IgAV) is the most common vasculitis of childhood. Renal involvement defines late morbidity of the disease. A better understanding of the pathophysiology of the progression to kidney disease and predictive biomarkers are required for better management of IgAV and its nephritis (IgAVN). OBJECTIVES: An untargeted metabolomics approach was performed to reveal the underlying molecular mechanism of disease pathogenesis and to define potential biomarkers from plasma samples from IgAV and IgAVN patients. METHODS: Forty-five active IgAV patients (H) and six healthy controls (C) were enrolled in the study. Plasma samples were collected on the same day of diagnosis and before any immunosuppressive treatment was initiated. At the time of diagnosis and sample collection, none of the patients had renal involvement. We used Quadrupole Time of Flight Mass Spectrometry (Q-TOF LC/MS) to investigate the alterations in plasma metabolomic profiles. Three separate pools were created: healthy controls (group C), active IgAV patients who did not develop renal involvement (group H), and patients who developed IgAVN at follow up (group N). Peak picking, grouping, and comparison parts were performed via XCMS (https://xcmsonline.scripps.edu/) software. RESULTS: At follow-up, IgAVN developed in 6 out of 45 IgAV patients. The median time of renal involvement development is 23 days (range 5-45 days). Of these, 3 had nephritic proteinuria, one had nephrotic proteinuria, and 2 had microscopic hematuria. There were no significant differences in gender, age, clinical manifestations, and laboratory findings between the six patients who developed renal involvement and those who did not. In multivariate analysis, there was no significant association between any of the defined demographic and clinical characteristics (male sex, gastrointestinal system involvement, joint involvement, CRP, WBC, PLT) and the occurrence of renal involvement. Totally 2618 peaks were detected for group H, N, and C. Among them, 355 peaks were found to be statistically significant and reliable (p<0.05), and 155 of these peaks were found to be changed (fold change >1.5) between the groups C and H, and 66 peaks were found to be changed (fold change >1.5) between the groups H and N. The number of the peaks on the intersection of the peaks found to be different between the groups (C and H) and (H and N) was 39. Based on putative identification results, 15 putatively identified metabolites matched with 11 peaks were presented as biomarker candidates after careful evaluation with a clinical perspective. CONCLUSION: We suggest that DHAP (18:0), prostaglandin D2/I2, porphobilinogen, 5-methyltetrahydrofolic acid, and N-Acetyl-4-O-acetylneuraminic acid/N-Acetyl-7-O-acetylneuraminic acid may serve as biomarkers for predicting kidney disease. Future studies with larger groups of IgAV patients are needed to validate the identified metabolic profile.
引用
- Demir S, Kaplan O, Celebier M, et al. Predictive biomarkers of IgA vasculitis with nephritis by metabolomic analysis. Semin Arthritis Rheum. 2020. PMID: 33065418. doi:10.1016/j.semarthrit.2020.09.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。